Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 4/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1076256 | 0.83 | ALDH1A1 (0.42) | LMNAMAPK1ALDH1A1KDM4EMEN1 | |
| SCHEMBL16712303 | 0.83 | KDM4E (0.30) | KDM4E | |
| SCHEMBL2315007 | 0.82 | ALDH1A1 (0.39) | LMNAMAPK1ALDH1A1KDM4EMEN1 | |
| SCHEMBL1077424 | 0.76 | SLC2A1 (0.43) | LMNAMAPK1ALDH1A1KDM4EMEN1 | |
| SCHEMBL1077415 | 0.73 | ALDH1A1 (0.50) | LMNAMAPK1ALDH1A1KDM4EMEN1 | |
| SCHEMBL2308765 | 0.72 | EGFR (0.40) | LMNAMAPK1ALDH1A1KDM4EMEN1 | |
| SCHEMBL1076313 | 0.72 | KDM4E (0.46) | LMNAMAPK1ALDH1A1KDM4EMEN1 | |
| SCHEMBL1075730 | 0.71 | L3MBTL1 (0.44) | LMNAMAPK1ALDH1A1KDM4EMEN1 | |
| SCHEMBL1077384 | 0.71 | ALDH1A1 (0.38) | LMNAMAPK1ALDH1A1KDM4EMEN1 | |
| SCHEMBL1077380 | 0.71 | ALDH1A1 (0.38) | LMNAMAPK1ALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2276732-B1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KAROBIO AB (SE) | 2015-05-20 | — | — | EP | claimed |
| CN-102066323-B | Novel estrogen receptor ligands | KAROBIO AB | 2015-05-13 | — | — | CN | claimed |
| US-8653072-B2 | Estrogen receptor ligands | KARO BIO AB (SE) | 2014-02-18 | — | — | US | claimed |
| US-20130131061-A1 | Novel Estrogen Receptor Ligands | KARO BIO AB (SE) | 2013-05-23 | — | — | US | claimed |
| US-8367665-B2 | Estrogen receptor ligands | KARO BIO AB (SE) | 2013-02-05 | — | — | US | claimed |
| US-20110190294-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | OASMIA PHARMACEUTICAL AB (SE) | 2011-08-04 | — | — | US | claimed |
| CN-102066323-A | Novel estrogen receptor ligands | KAROBIO AB | 2011-05-18 | — | — | CN | claimed |
| EP-2276732-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2011-01-26 | — | — | EP | claimed |
| WO-2009127686-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2009-10-22 | — | — | WO | claimed |
| EP-3782616-B1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | UNIV CALIFORNIA (US) | 2023-11-01 | — | — | EP | disclosed |
| US-11628146-B2 | Estrogen receptor ligand treatment for neurodegenerative diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-04-18 | — | — | US | disclosed |
| EP-3782616-A1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | The Regents of The University of California (US) | 2021-02-24 | — | — | EP | disclosed |
| US-20210008002-A1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-01-14 | — | — | US | disclosed |
| US-10758496-B2 | Estrogen receptor ligand treatment for neurodegenerative diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-01 | — | — | US | disclosed |
| US-8653072-B2 | Estrogen receptor ligands | KARO BIO AB (SE) | 2014-02-18 | — | — | US | disclosed |
| US-20130131061-A1 | Novel Estrogen Receptor Ligands | KARO BIO AB (SE) | 2013-05-23 | — | — | US | disclosed |
| US-8367665-B2 | Estrogen receptor ligands | KARO BIO AB (SE) | 2013-02-05 | — | — | US | disclosed |
| US-20110190294-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | OASMIA PHARMACEUTICAL AB (SE) | 2011-08-04 | — | — | US | disclosed |
| EP-2276732-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009127686-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008002-A1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | ESR2, ESRRG, ESR1 | LMNA 3275/4885MAPK1 2713/4885ALDH1A1 2803/4885 |
| US-11628146-B2 | Estrogen receptor ligand treatment for neurodegenerative diseases | ESR2, ESRRG, ESR1 | LMNA 3275/4885MAPK1 2713/4885ALDH1A1 2803/4885 |
| US-20130131061-A1 | Novel Estrogen Receptor Ligands | ESR1, GPER1, ESRRA | LMNA 3927/4885MAPK1 2293/4885ALDH1A1 1765/4885 |
| US-20110190294-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | ESR1, GPER1, ESRRA | LMNA 3887/4885MAPK1 2359/4885ALDH1A1 1909/4885 |
| US-10758496-B2 | Estrogen receptor ligand treatment for neurodegenerative diseases | ESR2, ESRRG, ESR1 | LMNA 3275/4885MAPK1 2713/4885ALDH1A1 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.